200 related articles for article (PubMed ID: 31448236)
1. NAMPT and NAPRT, Key Enzymes in NAD Salvage Synthesis Pathway, Are of Negative Prognostic Value in Colorectal Cancer.
Li XQ; Lei J; Mao LH; Wang QL; Xu F; Ran T; Zhou ZH; He S
Front Oncol; 2019; 9():736. PubMed ID: 31448236
[TBL] [Abstract][Full Text] [Related]
2. Extensive regulation of nicotinate phosphoribosyltransferase (NAPRT) expression in human tissues and tumors.
Duarte-Pereira S; Pereira-Castro I; Silva SS; Correia MG; Neto C; da Costa LT; Amorim A; Silva RM
Oncotarget; 2016 Jan; 7(2):1973-83. PubMed ID: 26675378
[TBL] [Abstract][Full Text] [Related]
3. NAD Synthesis Pathway Interference Is a Viable Therapeutic Strategy for Chondrosarcoma.
Peterse EFP; van den Akker BEWM; Niessen B; Oosting J; Suijker J; de Jong Y; Danen EHJ; Cleton-Jansen AM; Bovée JVMG
Mol Cancer Res; 2017 Dec; 15(12):1714-1721. PubMed ID: 28860121
[TBL] [Abstract][Full Text] [Related]
4. Discovery of a novel NAMPT inhibitor that selectively targets NAPRT-deficient EMT-subtype cancer cells and alleviates chemotherapy-induced peripheral neuropathy.
Kim M; Kim H; Kang BG; Lee J; Kim T; Lee H; Jung J; Oh MJ; Seo S; Ryu MJ; Sung Y; Lee Y; Yeom J; Han G; Cha SS; Jung H; Kim HS
Theranostics; 2023; 13(14):5075-5098. PubMed ID: 37771778
[No Abstract] [Full Text] [Related]
5. Properly Substituted Benzimidazoles as a New Promising Class of Nicotinate Phosphoribosyltransferase (NAPRT) Modulators.
Baldassarri C; Giorgioni G; Piergentili A; Quaglia W; Fontana S; Mammoli V; Minazzato G; Marangoni E; Gasparrini M; Sorci L; Raffaelli N; Cappellacci L; Petrelli R; Del Bello F
Pharmaceuticals (Basel); 2023 Jan; 16(2):. PubMed ID: 37259338
[TBL] [Abstract][Full Text] [Related]
6. Nicotinic Acid Phosphoribosyltransferase Regulates Cancer Cell Metabolism, Susceptibility to NAMPT Inhibitors, and DNA Repair.
Piacente F; Caffa I; Ravera S; Sociali G; Passalacqua M; Vellone VG; Becherini P; Reverberi D; Monacelli F; Ballestrero A; Odetti P; Cagnetta A; Cea M; Nahimana A; Duchosal M; Bruzzone S; Nencioni A
Cancer Res; 2017 Jul; 77(14):3857-3869. PubMed ID: 28507103
[TBL] [Abstract][Full Text] [Related]
7. A Versatile Continuous Fluorometric Enzymatic Assay for Targeting Nicotinate Phosphoribosyltransferase.
Minazzato G; Marangoni E; Fortunato C; Petrelli R; Cappellacci L; Del Bello F; Sorci L; Gasparrini M; Piacente F; Bruzzone S; Raffaelli N
Molecules; 2023 Jan; 28(3):. PubMed ID: 36770640
[TBL] [Abstract][Full Text] [Related]
8. Novel NAPRT specific antibody identifies small cell lung cancer and neuronal cancers as promising clinical indications for a NAMPT inhibitor/niacin co-administration strategy.
Cole J; Guiot MC; Gravel M; Bernier C; Shore GC; Roulston A
Oncotarget; 2017 Sep; 8(44):77846-77859. PubMed ID: 29100430
[TBL] [Abstract][Full Text] [Related]
9. Personalized quantitative models of NAD metabolism in hepatocellular carcinoma identify a subgroup with poor prognosis.
Chedere A; Mishra M; Kulkarni O; Sriraman S; Chandra N
Front Oncol; 2022; 12():954512. PubMed ID: 36249025
[TBL] [Abstract][Full Text] [Related]
10. Targeting the NAD Salvage Synthesis Pathway as a Novel Therapeutic Strategy for Osteosarcomas with Low NAPRT Expression.
Franceschini N; Oosting J; Tamsma M; Niessen B; Bruijn IB; van den Akker B; Kruisselbrink AB; Palubeckaitė I; Bovée JVMG; Cleton-Jansen AM
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34200964
[TBL] [Abstract][Full Text] [Related]
11. Selective Cytotoxicity of the NAMPT Inhibitor FK866 Toward Gastric Cancer Cells With Markers of the Epithelial-Mesenchymal Transition, Due to Loss of NAPRT.
Lee J; Kim H; Lee JE; Shin SJ; Oh S; Kwon G; Kim H; Choi YY; White MA; Paik S; Cheong JH; Kim HS
Gastroenterology; 2018 Sep; 155(3):799-814.e13. PubMed ID: 29775598
[TBL] [Abstract][Full Text] [Related]
12. NAPRT, but Not NAMPT, Provides Additional Support for NAD Synthesis in Esophageal Precancerous Lesions.
Wang N; Pan D; Wang X; Su M; Wang X; Yan Q; Sun G; Wang S
Nutrients; 2022 Nov; 14(22):. PubMed ID: 36432602
[TBL] [Abstract][Full Text] [Related]
13. Identification of NAPRT Inhibitors with Anti-Cancer Properties by In Silico Drug Discovery.
Ghanem MS; Caffa I; Del Rio A; Franco J; Parenti MD; Monacelli F; Cea M; Khalifa A; Nahimana A; Duchosal MA; Ravera S; Bertola N; Bruzzone S; Nencioni A; Piacente F
Pharmaceuticals (Basel); 2022 Jul; 15(7):. PubMed ID: 35890147
[TBL] [Abstract][Full Text] [Related]
14. NAD metabolic dependency in cancer is shaped by gene amplification and enhancer remodelling.
Chowdhry S; Zanca C; Rajkumar U; Koga T; Diao Y; Raviram R; Liu F; Turner K; Yang H; Brunk E; Bi J; Furnari F; Bafna V; Ren B; Mischel PS
Nature; 2019 May; 569(7757):570-575. PubMed ID: 31019297
[TBL] [Abstract][Full Text] [Related]
15. Inhibitors of NAD
Ghanem MS; Caffa I; Monacelli F; Nencioni A
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396769
[TBL] [Abstract][Full Text] [Related]
16. NAMPT and NAPRT: Two Metabolic Enzymes With Key Roles in Inflammation.
Audrito V; Messana VG; Deaglio S
Front Oncol; 2020; 10():358. PubMed ID: 32266141
[TBL] [Abstract][Full Text] [Related]
17.
Lucena-Cacace A; Otero-Albiol D; Jiménez-García MP; Muñoz-Galvan S; Carnero A
Clin Cancer Res; 2018 Mar; 24(5):1202-1215. PubMed ID: 29203587
[No Abstract] [Full Text] [Related]
18. Expression patterns of nicotinamide phosphoribosyltransferase and nicotinic acid phosphoribosyltransferase in human malignant lymphomas.
Olesen UH; Hastrup N; Sehested M
APMIS; 2011 Apr; 119(4-5):296-303. PubMed ID: 21492230
[TBL] [Abstract][Full Text] [Related]
19. Structure-Based Identification and Biological Characterization of New NAPRT Inhibitors.
Franco J; Piacente F; Walter M; Fratta S; Ghanem M; Benzi A; Caffa I; Kurkin AV; Altieri A; Herr P; Martínez-Bailén M; Robina I; Bruzzone S; Nencioni A; Del Rio A
Pharmaceuticals (Basel); 2022 Jul; 15(7):. PubMed ID: 35890155
[TBL] [Abstract][Full Text] [Related]
20. Nicotinamide phosphoribosyltransferase expression and clinical outcome of resected stage I/II pancreatic ductal adenocarcinoma.
Davis K; Dunseth CD; Mott SL; Cramer-Morales KL; Miller AM; Ear PH; Mezhir JJ; Bellizzi AM; Chan CHF
PLoS One; 2019; 14(3):e0213576. PubMed ID: 30856230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]